Equities Analysts Offer Predictions for ALLO Q3 Earnings

Key Points

• William Blair has lowered its Q3 2025 earnings per share (EPS) estimate for Allogene Therapeutics to ($0.25), down from ($0.23), indicating growing concerns about the company's financial outlook.
• The consensus estimate for Allogene's full-year earnings is currently projected at ($1.28) per share, with further downward adjustments anticipated for subsequent quarters through 2026.
• Despite recent earnings beat in Q2 2025, showing a loss of ($0.23) per share against an estimate of ($0.28), analyst sentiment remains cautious, with several firms lowering price targets for the stock.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at William Blair reduced their Q3 2025 EPS estimates for shares of Allogene Therapeutics in a research report issued to clients and investors on Thursday, August 14th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($0.25) per share for the quarter, down from their previous forecast of ($0.23). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics' Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($0.79) EPS.

A number of other research firms also recently weighed in on ALLO. Robert W. Baird decreased their price target on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Citigroup lowered their target price on shares of Allogene Therapeutics from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Citizens Jmp cut shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 14th. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a research note on Wednesday, May 14th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.44.

Allogene Therapeutics Price Performance

NASDAQ:ALLO traded up $0.0350 on Monday, reaching $1.0950. The stock had a trading volume of 2,054,835 shares, compared to its average volume of 4,379,342. The company has a market cap of $242.96 million, a price-to-earnings ratio of -0.99 and a beta of 0.35. Allogene Therapeutics has a 12-month low of $0.8621 and a 12-month high of $3.78. The firm's fifty day moving average is $1.23 and its two-hundred day moving average is $1.44.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05.

Institutional Trading of Allogene Therapeutics

A number of large investors have recently bought and sold shares of the stock. Two Sigma Advisers LP grew its holdings in shares of Allogene Therapeutics by 12.1% during the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company's stock worth $5,756,000 after purchasing an additional 291,800 shares during the last quarter. Hsbc Holdings PLC grew its holdings in shares of Allogene Therapeutics by 32.0% during the fourth quarter. Hsbc Holdings PLC now owns 69,155 shares of the company's stock worth $147,000 after purchasing an additional 16,768 shares during the last quarter. DAFNA Capital Management LLC grew its holdings in shares of Allogene Therapeutics by 18.1% during the fourth quarter. DAFNA Capital Management LLC now owns 1,240,118 shares of the company's stock worth $2,641,000 after purchasing an additional 190,000 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Allogene Therapeutics during the fourth quarter valued at $7,345,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Allogene Therapeutics by 23.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 305,895 shares of the company's stock valued at $651,000 after purchasing an additional 58,331 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).